Ireland
--:--IST
Recruiting Not applicable

The Effectiveness of Dextrose Prolotherapy in Patients With Coccydynia

NCT07552298 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2025-06-15
Last updated
2026-04-27

Condition(s) studied

Coccydynia

Investigational drug(s) / intervention(s)

Dextrose prolotherapy (DPT)Physiological Saline Injection

Dextrose prolotherapy (DPT): Coccyx injection: Using a sterile 27-gauge syringe (dental needle), a total of 10 cc of solution (5 cc of 30% dextrose + 4 cc of physiological saline + 1 cc of 1% lidocaine solution) will be injected perpendicularly to the surface at the previously marked attachment points of the sacrococcygeal-sacro-tuberous ligaments to the sacrum and along the entire coccyx.

Physiological Saline Injection: Saline + lidocaine group injection protocol: Using a sterile 30-gauge syringe (insulin needle), a total of 10 cc of solution (5 cc of physiological saline + 5 cc of 1% lidocaine solution) will be injected into the previously marked tendon attachment points on the bone.

Study summary

In this prospective, randomized, controlled, double-blinded study, we aimed to evaluate the effects of Dextrose Prolotherapy injections in patients with coccydynia.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Patients with coccydynia lasting longer than 6 months, * Those unresponsive to at least 6 months of conventional conservative treatment methods, * Those with coccygeal tenderness on palpation, * Patients aged between 18 and 65 years. Exclusion Criteria: * Patients with a history of trauma within the last 3 months or postpartum coccydynia, * Those with lesions or infections at the injection site, * Those with dislocation or organic bone pathology of the coccyx observed on X-ray imaging, * Those with fecal or urinary incontinence, * Patients with poorly controlled diabetes mellitus, * Those with a history of malignancy, * Patients with a bleeding tendency (acquired or hereditary) \[INR \> 2 in patients using warfarin\], * Those with a history of myelomeningocele, * Those diagnosed with spina bifida, * Patients with rheumatologic disease, * Those who have undergone coccyx injection or ganglion block within the last 3 months, * Patients with severe comorbidities.

Primary outcome measure(s)

  • Visual Analog Scale — Before treatment, and at the 1st, 3rd, and 6th months following treatment
    Pain intensity during sitting and activity

Trial sites (1)

FacilityCityRegionStatus
Istanbul University Istanbul Faculty of Medicine, Department of Physical Medicine and Rehabilitation Istanbul Turkey (Türkiye) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07552298 on ClinicalTrials.gov ↗ ← All trials in Turkey